Drug Profile
Research programme: cell based inflammatory bowel disease therapeutics: Icahn School of Medicine/Takeda/University of Chicago
Latest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator Icahn School of Medicine at Mount Sinai; Takeda Pharmaceuticals USA; University of Chicago
- Class Cell therapies
- Mechanism of Action Immunomodulators; Inflammation mediator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for research development in Inflammatory-bowel-diseases in USA
- 31 Mar 2016 Takeda Pharmaceuticals, Icahn School of Medicine at Mount Sinai and University of Chicago agree to co-develop cell based inflammatory bowel therapeutics in USA for Inflammatory bowel disaese
- 31 Mar 2016 Early research in Inflammatory bowel disease in USA (unspecified route)